Comesis in patients with breast neoplasia submitted to the hypofractionated radiotherapy with of intensity-modulated beam

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP MIRANDA, Fabiana Accioli
VIEIRA, Marina Tamm Lannes
MORAES, Fabio Ynoe de
MARTA, Gustavo Nader FMUSP-HC
CARVALHO, Heloisa de Andrade FMUSP-HC
HANNA, Samir Abdallah 2018
dc.identifier.citation REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.64, n.11, p.1023-1030, 2018
dc.identifier.issn 0104-4230
dc.description.abstract OBJECTIVE: To assess the cosmetic satisfaction of patients diagnosed with breast cancer submitted to the hypofractionated radiotherapy with IMRT (hIMRT) technique and its correlation with dosimetric data of the radiotherapy planning. MATERIALS AND METHODS: The retrospective cohort study that assessed women with a diagnosis of malignant breast neoplasia submitted to the conservative treatment or radical mastectomy and treated with hIMRT. In the period between August 2007 to December 2014, in a philanthropic/private institution, 170 records were selected. The cosmetic assessment was corned out by means of the Harvard/RTOG/NSABP scale with one-year minimum range after treatment. The collected dosimetric data were: breast/chest wall volume, volume that received 95% (V95%) and 107% (V107%) of the prescribed dose. RESULTS: The volume of the treated breasts ranged from 169 to 2.103 ml (median = 702; IQR: 535 to 914 ml). Median V95% was 86.7% (54.6-96.6%; IQR: 80.0% to 90.6%); eight (5.7%) patients had V95% higher than 95%. Median V107% was 0% (0%-16.3%; IQR: 0.0% to 0.3% and 13); 9.3% patients had V107% higher than 2%. One hundred and thirty-three (78.2%) patients responded to the cosmetic assessment: 99 (74.4%) considered the cosmetic results excellent. Significant associations between cosmetic assessment and breast volume (p=0.875), V95% (p=0.294) e V107% (p=0.301) were not found. CONCLUSION: The cosmetic results showed favorable when using hIMRT, and the lack of correlation with usual the dosimetric data illustrates the capacity of hIMRT to minimize the heterogeneity of the dose in this endpoint, even in voluminous breasts.
dc.language.iso eng
dc.relation.ispartof Revista da Associacao Medica Brasileira
dc.rights openAccess
dc.subject Hypofractionation; Breast neoplasia; Radiotherapy
dc.subject.other radiation-therapy; randomized-trial; dose-response; cancer; irradiation; fractionation; standard; women; size; rtog
dc.title Comesis in patients with breast neoplasia submitted to the hypofractionated radiotherapy with of intensity-modulated beam
dc.type article
dc.rights.holder Copyright ASSOC MEDICA BRASILEIRA
dc.identifier.doi 10.1590/1806-9282.64.11.1023
dc.identifier.pmid 30570055
dc.type.category original article
dc.type.version publishedVersion MARTA, Gustavo Nader:HC:ICESP CARVALHO, Heloisa de Andrade:FM:MDR · MIRANDA, Fabiana Accioli:Hosp Sirio Libanes SP, Radiote, Sao Paulo, SP, Brazil
· VIEIRA, Marina Tamm Lannes:COI Clin Oncol Integradas RJ, Rio De Janeiro, RJ, Brazil
· MORAES, Fabio Ynoe de:Univ Toronto, Radiat Med Program, Princess Margaret Hosp, Toronto, ON, Canada
· HANNA, Samir Abdallah:Hosp Sirio Libanes SP, Sao Paulo, SP, Brazil WOS:000453021400012 2-s2.0-85058864530 SAO PAULO BRAZIL
hcfmusp.relation.reference · Abe O, 2005, LANCET, V366, P2087
· ARCHAMBEAU JO, 1995, INT J RADIAT ONCOL, V31, P1171, DOI 10.1016/0360-3016(94)00423-I
· Awwad HK, 1990, RAD ONCOLOGY RADIOBI, P129
· Bartelink H, 2008, LANCET, V371, P1050, DOI 10.1016/S0140-6736(08)60349-9
· Bentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7
· Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)70077-9, 10.1016/S1470-2045(08)60348-7]
· Bentzen SM, 2005, ACTA ONCOL, V44, P825, DOI 10.1080/02841860500374471
· Coles CE, 2005, CLIN ONCOL-UK, V17, P98, DOI 10.1016/j.colon.2004.08.010
· COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C
· Curran D, 1998, EUR J CANCER, V34, P307, DOI 10.1016/S0959-8049(97)00312-2
· De Gersem W, 2001, INT J RADIAT ONCOL, V51, P1371, DOI 10.1016/S0360-3016(01)02607-4
· Deantonio L, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-112
· Donovan E, 2007, RADIOTHER ONCOL, V82, P254, DOI 10.1016/j.radonc.2006.12.008
· Donovan EM, 2000, INT J RADIAT ONCOL, V46, P671, DOI 10.1016/S0360-3016(99)00388-0
· Freedman GM, 2007, INT J RADIAT ONCOL, V68, P347, DOI 10.1016/j.ijrobp.2006.12.035
· Harsolia H., 2007, J RAD ONCOLOGY, V68
· Haviland JS, 2013, LANCET ONCOL, V14, P1086, DOI 10.1016/S1470-2045(13)70386-3
· Holloway CL, 2010, BREAST, V19, P163, DOI 10.1016/j.breast.2010.03.002
· MOODY AM, 1994, RADIOTHER ONCOL, V33, P106, DOI 10.1016/0167-8140(94)90063-9
· Mukesh B., 2013, JCO, V31
· Owen JR, 2006, LANCET ONCOL, V7, P467, DOI 10.1016/S1470-2045(06)70699-4
· Plataniotis GA, 2009, INT J RADIAT ONCOL, V75, P512, DOI 10.1016/j.ijrobp.2009.05.013
· RUBIN P, 1995, INT J RADIAT ONCOL, V31, P1041, DOI 10.1016/0360-3016(95)00057-6
· Smith BD, 2018, PRACT RAD ONCOL
· Smith BD, 2011, INT J RADIAT ONCOL, V81, P59, DOI 10.1016/j.ijrobp.2010.04.042
· Sun G. Y., INT J RAD ONCOLOGY B, V99, pS3
· Taher Azza N, 2004, J Egypt Natl Canc Inst, V16, P178
· Taylor C, 2017, J CLIN ONCOLOGY
· Vicini FA, 2002, INT J RADIAT ONCOL, V54, P1336, DOI 10.1016/S0360-3016(02)03746-X
· Whelan T, 2002, J NATL CANCER I, V94, P1143
· Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260
· Yarnold J, 2005, RADIOTHER ONCOL, V75, P9, DOI 10.1016/j.radonc.2005.01.005
· Yarnold J, 2011, INT J RADIAT ONCOL, V79, P1, DOI 10.1016/j.ijrobp.2010.08.035
dc.description.index MEDLINE
hcfmusp.citation.scopus 3
hcfmusp.citation.wos 3 Brasil Canadá

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account